Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at Cantor Fitzgerald

Posted by Geri Gentry on Sep 29th, 2026

Cantor Fitzgerald initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage issued an overweight rating and a $8.00 target price on the biopharmaceutical company’s stock.

LXRX has been the topic of a number of other research reports. Weiss Ratings upgraded shares of Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Zacks Research downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Wall Street Zen lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.70.

Get Our Latest Research Report on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Price Performance

NASDAQ:LXRX opened at $1.90 on Monday. Lexicon Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $2.68. The firm has a market cap of $845.42 million, a price-to-earnings ratio of -12.67 and a beta of 1.02. The company’s 50-day moving average is $2.23 and its two-hundred day moving average is $2.05. The company has a current ratio of 13.37, a quick ratio of 13.29 and a debt-to-equity ratio of 0.29.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.69 million for the quarter, compared to analysts’ expectations of $3.99 million. Lexicon Pharmaceuticals had a negative return on equity of 37.53% and a negative net margin of 147.38%. Research analysts expect that Lexicon Pharmaceuticals will post -0.17 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. WINTON GROUP Ltd lifted its stake in shares of Lexicon Pharmaceuticals by 69.4% in the 2nd quarter. WINTON GROUP Ltd now owns 43,200 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 17,700 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $28,000. AXQ Capital LP increased its position in Lexicon Pharmaceuticals by 126.9% during the 2nd quarter. AXQ Capital LP now owns 45,727 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 25,577 shares in the last quarter. Wellington Management Group LLP acquired a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $431,000. Finally, Bank of New York Mellon Corp purchased a new position in Lexicon Pharmaceuticals in the second quarter valued at approximately $1,365,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

Positive Sentiment: Cantor Fitzgerald said Lexicon has an “unencumbered path” toward expanding sotagliflozin into HCM and established an $8 target, providing a strong analyst-driven catalyst. Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target
Positive Sentiment: Coverage from a prominent research firm characterized LXRX as a clear buy at its current valuation, citing sotagliflozin’s potential to win FDA approval for a new indication. Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Positive Sentiment: Additional reports highlighted Cantor Fitzgerald’s bullish HCM outlook, reinforcing investor expectations for a potentially important new use of sotagliflozin. Lexicon Pharmaceuticals Surges as Cantor Fitzgerald Sees Unencumbered Path in HCM
Neutral Sentiment: Other analyst-tracking reports placed the average price target around $5.70, still well above the recent share price, though these targets remain dependent on clinical and regulatory execution. Lexicon Pharmaceuticals Stock Has Average Target Price of $5.70

Lexicon Pharmaceuticals Company Profile

(Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company that discovers and develops medicines for human disease. Founded in 1995 and headquartered in The Woodlands, Texas, the company uses its drug-discovery platform and expertise in biology to identify potential treatments for conditions with significant unmet medical needs.

Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral medicine used to treat carcinoid syndrome diarrhea in adults whose symptoms are not adequately controlled by somatostatin analog therapy.